Intersect ENT, Inc. (XENT)
Stock Price:
$20.49 USD
-0.90 (-4.21%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
670.07M |
| Revenue (ttm) |
85.42M |
| Net Income (ttm) |
-61.46M |
| Shares Out |
32.70M |
| EPS (ttm) |
-1.92 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 11, 2020 |
| Last Price |
$20.49 |
| Previous Close |
$21.39 |
| Change ($) |
-0.90 |
| Change (%) |
-4.21% |
| Day's Open |
21.50 |
| Day's Range |
20.35 - 21.69 |
| Day's Volume |
638,181 |
| 52-Week Range |
5.97 - 31.46 |
More Stats
| Market Cap |
670.07M |
| Enterprise Value |
607.75M |
| Earnings Date (est) |
Oct 29, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
32.70M |
| Float |
29.16M |
| EPS (basic) |
-1.91 |
| EPS (diluted) |
-1.92 |
| FCF / Share |
-1.05 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.38M |
| Short Ratio |
2.34 |
| Short % of Float |
4.32% |
| Beta |
1.29 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
7.84 |
| PB Ratio |
7.28 |
| Revenue |
85.42M |
| Operating Income |
-60.93M |
| Net Income |
-61.46M |
| Free Cash Flow |
-34.05M |
| Net Cash |
62.31M |
| Net Cash / Share |
1.91 |
| Gross Margin |
102.29% |
| Operating Margin |
-71.34% |
| Profit Margin |
-72.00% |
| FCF Margin |
-39.86% |
| ROA |
-21.97% |
| ROE |
-59.33% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (9)
| Buy |
3 |
| Overweight |
0 |
| Hold |
6 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$20.42*
(-0.34% downside)
Low
16.0
Current: $20.49
High
30.0
Target: 20.42
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 109 | 108 | 96.30 | 78.71 | 61.59 | 38.59 | 17.93 | 5.86 |
| Revenue Growth | 0.62% | 12.64% | 22.35% | 27.79% | 59.62% | 115.2% | 205.83% | - |
| Gross Profit | 87.37 | 85.86 | 80.80 | 65.71 | 49.31 | 28.36 | 9.78 | 2.03 |
| Operating Income | -45.39 | -25.01 | -17.60 | -26.11 | -26.94 | -18.08 | -17.97 | -16.49 |
| Net Income | -42.99 | -22.92 | -16.36 | -25.22 | -26.63 | -18.36 | -18.37 | -16.37 |
| Shares Outstanding | 31.39 | 30.31 | 29.12 | 28.42 | 26.16 | 11.38 | 1.46 | 1.00 |
| Earnings Per Share | -1.37 | -0.76 | -0.56 | -0.89 | -1.02 | -1.61 | -12.57 | -16.38 |
| Operating Cash Flow | -27.25 | -13.84 | -8.04 | -20.06 | -20.09 | -17.95 | -19.10 | -16.15 |
| Capital Expenditures | -3.73 | -2.12 | -2.28 | -2.07 | -1.52 | -0.37 | -0.47 | -1.41 |
| Free Cash Flow | -30.98 | -15.96 | -10.32 | -22.13 | -21.61 | -18.32 | -19.57 | -17.56 |
| Cash & Equivalents | 90.64 | 101 | 102 | 104 | 124 | 48.44 | 12.29 | 2.12 |
| Total Debt | 10.89 | - | - | - | - | - | 1.45 | 2.00 |
| Net Cash / Debt | 79.75 | 101 | 102 | 104 | 124 | 48.44 | 10.84 | 0.12 |
| Assets | 148 | 141 | 136 | 130 | 145 | 62.95 | 21.04 | 7.23 |
| Liabilities | 29.84 | 19.97 | 18.36 | 15.38 | 14.40 | 9.14 | 6.89 | 65.95 |
| Book Value | 118 | 121 | 117 | 114 | 130 | 53.81 | -76.62 | -58.72 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Intersect ENT, Inc. |
| Country |
United States |
| Employees |
402 |
| CEO |
Thomas A. West |
Stock Information
| Ticker Symbol |
XENT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NASDAQ: XENT |
| IPO Date |
July 24, 2014 |
Description
Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.